FIGURE 4.

GW6471 reduced obesity and NASH dependent on intestinal PPARα. (A–C) The therapeutic effect of GW6471 in HFD‐induced obesity and fatty liver was examined (n = 5). (A) Liver weight and index, hepatic TG and TC, and serum ALT, TC, and TG. (B) Intestinal FABP1 protein in HFD‐fed mice. (C) Representative H&E staining; scale bar 50 µm. (D–F) The therapeutic effect of GW6471 in HFCFD‐induced NASH were examined (n = 5–8). (D) Liver weight and index, hepatic TG and TC, and serum ALT, TC, TG, and NEFA. (E) Representative H&E, Oil Red O, and Sirius Red staining (scale bar, 100 µm) and mRNA levels of hepatic fibrogenesis and inflammation‐related genes (n = 5–8). (F) Intestinal FABP1 protein in HFCFD‐fed mice. *p < 0.05, **p < 0.01, ***p < 0.001